Lupin reports strong quarter and half-year results, zero FDA observations

Lupin Limited reported consolidated total revenue from operations of ₹70,475.1 million for the quarter ended September 30, 2025, and ₹133,158.5 million for the half-year ended the same date. The company’s consolidated net profit after tax for the quarter was ₹14,848.3 million, with a half-year figure of ₹27,062.9 million. Basic earnings per share (EPS) for the quarter stood at ₹32.36, and for the half-year, it was ₹59.05.

In a separate announcement, Lupin confirmed its Bioresearch Centre in Pune received zero 483 observations from the U.S. Food and Drug Administration (FDA) following an onsite clinical inspection from November 3 to November 6, 2025. A bio-analytical remote regulatory assessment from October 30 to November 7, 2025, also concluded with no observations. Nilesh Gupta, managing director, emphasized that this outcome underscores Lupin's commitment to quality and compliance.

These announcements collectively highlight Lupin’s strong financial health and adherence to international quality standards, positioning it for continued growth in the global pharmaceutical market.